https://www.selleckchem.com/products/lw-6.html
Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network. Demographics, disease history/status/treatment, patient preferencesand HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC. Among 104 patients (median age 53.0 years, 67.3% female, 40.0% employe
Like
Comment
Share
